iPLEDGE REMS: FDA Panel To Consider Changing Pregnancy Testing, Counseling Requirements

 
• By Brenda Sandburg

Advisory committee to discuss proposed changes to isotretinoin REMS to minimize burden and treatment delays while preventing risk of fetal exposure. Agency recommends against at-home pregnancy tests.

Isotretinoin
US FDA advisory committee to vote on changes to isotretinoin iPLEDGE REMS • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers